NYSE:PFE - New York Stock Exchange, Inc. - US7170811035 - Common Stock - Currency: USD
24.2
+0.27 (+1.13%)
The current stock price of PFE is 24.2 USD. In the past month the price decreased by -0.37%. In the past year, price decreased by -12.98%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 59.86 | 780.78B | ||
JNJ | JOHNSON & JOHNSON | 15.53 | 375.64B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 20.07 | 307.32B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.75 | 225.73B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 19.47 | 224.59B | ||
MRK | MERCK & CO. INC. | 10.68 | 209.31B | ||
SNY | SANOFI-ADR | 14.4 | 135.72B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.89 | 102.91B | ||
GSK | GSK PLC-SPON ADR | 7.16 | 79.05B | ||
ZTS | ZOETIS INC | 26.59 | 70.23B | ||
HLN | HALEON PLC-ADR | 22.29 | 48.25B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 33.3 | 48.22B |
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 81,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
PFIZER INC
66 Hudson Boulevard East
New York City NEW YORK 10017 US
CEO: Albert Bourla
Employees: 81000
Phone: 12127332323
The current stock price of PFE is 24.2 USD. The price increased by 1.13% in the last trading session.
The exchange symbol of PFIZER INC is PFE and it is listed on the New York Stock Exchange, Inc. exchange.
PFE stock is listed on the New York Stock Exchange, Inc. exchange.
28 analysts have analysed PFE and the average price target is 29.71 USD. This implies a price increase of 22.77% is expected in the next year compared to the current price of 24.2. Check the PFIZER INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PFIZER INC (PFE) has a market capitalization of 137.25B USD. This makes PFE a Large Cap stock.
PFIZER INC (PFE) currently has 81000 employees.
PFIZER INC (PFE) has a support level at 21.91 and a resistance level at 25.39. Check the full technical report for a detailed analysis of PFE support and resistance levels.
The Revenue of PFIZER INC (PFE) is expected to decline by -0.2% in the next year. Check the estimates tab for more information on the PFE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PFIZER INC (PFE) has a dividend yield of 7.19%. The yearly dividend amount is currently 1.68. Check the full fundamental report for a detailed analysis of PFE dividend history, reliability and sustainability.
PFIZER INC (PFE) will report earnings on 2025-07-28, before the market open.
The PE ratio for PFIZER INC (PFE) is 7.54. This is based on the reported non-GAAP earnings per share of 3.21 and the current share price of 24.2 USD. Check the full fundamental report for a full analysis of the valuation metrics for PFE.
The outstanding short interest for PFIZER INC (PFE) is 1.9% of its float. Check the ownership tab for more information on the PFE short interest.
ChartMill assigns a technical rating of 1 / 10 to PFE. When comparing the yearly performance of all stocks, PFE is a bad performer in the overall market: 70.29% of all stocks are doing better.
ChartMill assigns a fundamental rating of 6 / 10 to PFE. While PFE belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Over the last trailing twelve months PFE reported a non-GAAP Earnings per Share(EPS) of 3.21. The EPS increased by 126.06% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 12.62% | ||
ROA | 3.76% | ||
ROE | 9.11% | ||
Debt/Equity | 0.69 |
ChartMill assigns a Buy % Consensus number of 70% to PFE. The Buy consensus is the average rating of analysts ratings from 28 analysts.
For the next year, analysts expect an EPS growth of -3.97% and a revenue growth -0.2% for PFE